CeNeRx raises $4.85M for TriRima trial, CNS agents

12/15/2011 | Pharmaceutical Business Review Online

CeNeRx BioPharma has secured $4.85 million in funding from investors including L Capital Partners and Omega Funds. The company will use the money to finish its second-phase trial of TriRima, its new antidepressant formulation, and to advance agents for disorders of the central nervous system.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care